Valuation: Norda ASA

Market Cap 513M 54.97M 47.15M 44.03M 40.4M 75.96M 5.25B 77.21M 520M 203M 2.64B 206M 202M 8.71B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.32M 24.29M 22.68M 20.81M 39.13M 2.71B 39.78M 268M 105M 1.36B 106M 104M 4.49B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
6 months+1.53%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 2013-04-07
Director TitleAgeSince
Chairman 54 2014-01-30
Director/Board Member 68 2013-06-19
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+6.67%+110.73% 47.49M
+2.37%+2.30%+3.39%+22.74% 50.5B
-0.62%+4.58%+487.47%+624.71% 46.01B
+2.09%+4.96%+20.59%+95.21% 42.85B
+3.85%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+3.04%+1.89%+31.62%+143.62% 16.98B
+4.33%+1.63% - - 17.05B
+1.44%+1.52%+4.22%+31.00% 14.3B
+3.87%+1.98%+82.99%+45.80% 13.84B
Average +2.12%+1.10%+76.05%+126.48% 27.46B
Weighted average by Cap. +1.88%+0.94%+104.88%+154.14%

Financials

2023 2024
Net sales 86.92M 9.31M 7.99M 7.46M 6.84M 12.87M 890M 13.08M 88M 34.46M 446M 34.96M 34.2M 1.48B 372M 39.83M 34.17M 31.9M 29.27M 55.04M 3.81B 55.95M 376M 147M 1.91B 150M 146M 6.31B
Net income 31.17M 3.34M 2.86M 2.67M 2.45M 4.61M 319M 4.69M 31.56M 12.36M 160M 12.54M 12.26M 529M 126M 13.49M 11.57M 10.81M 9.91M 18.64M 1.29B 18.95M 128M 49.93M 647M 50.65M 49.55M 2.14B
Net Debt -311M -33.34M -28.6M -26.7M -24.5M -46.07M -3.19B -46.83M -315M -123M -1.6B -125M -122M -5.28B -249M -26.65M -22.86M -21.35M -19.59M -36.83M -2.55B -37.44M -252M -98.64M -1.28B -100M -97.9M -4.22B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock